Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) on July 21, bringing the price target down to $92 from $115.

The analyst told investors that Merck & Co., Inc.’s (NYSE:MRK) focus on the expansion of its cardiopulmonary and infectious disease franchises is anticipated to boost investor sentiment, especially because these domains show considerable development potential.

Graybosch reasoned that while challenges such as the regulatory pressures on Gardasil and Keytruda exist, Merck & Co., Inc.’s (NYSE:MRK) valuation remains attractive in comparison to its peers, which shows room for optimism and appreciation.

In addition, upcoming clinical trial results may also bolster Merck & Co., Inc.’s (NYSE:MRK) long-term revenue prospects according to the analyst, including those for enlicitide and Winrevair.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.